Protect Your Portfolio Against Market Uncertainty
- Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
- Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
An update from Acrux Limited ( (AU:ACR) ) is now available.
Acrux Limited, in partnership with TruPharma, has launched a new 90 gram pack size of Dapsone 5% Gel in the United States, a topical prescription medicine used to treat acne vulgaris. This strategic move aims to enhance the product’s competitive profile and market share, despite the 90 gram size representing only 16% of the market volume. The annual market sales for Dapsone 5% Gel products exceeded US$15.8 million as of August 2024.
More about Acrux Limited
Acrux Limited is a specialty pharmaceutical company with a proven ability in developing and commercializing topically applied pharmaceutical products. With 25 years of experience, the company focuses on formulating and developing a range of topical generic products, primarily for the U.S. market, leveraging its skilled workforce and facilities.
YTD Price Performance: 0.0%
Average Trading Volume: 3,250
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $7.96M
Find detailed analytics on ACR stock on TipRanks’ Stock Analysis page.